Never hurts to take profit! Thats what its all about! I just have a small position, willing to take the risk... But the approval seems inevitable to me:
-Never seen so much confidence with analysts & writers in approval for a biotech stock. -FDA set the clinical endpoints of the Phase III study and Vimovo met them all with statistically clinical significance in efficacy & safety. This is even after the FDA changed the endpoints temporarily only for them to come to agreement with POZN that no changes needed to be made. - Esomeprazole (approved in a delayed release form as Nexium) is already approved for combination use with naproxen (an approved OTC drug at lower doses).
News 
Market Data 
Discover 
AI
